Reprogramming of pro-tumor macrophages by hydroxychloroquine in an abdominally metastasized diffuse midline glioma

Cristian Ruiz-Moreno^{1,2}, Farid Keramati^{1,2}, Peter Brazda¹, Wout Megchelenbrink^{1,3}, Brigit te Pas¹, Kim Boshuisen¹, Helena C. Besse⁴, Lennart Kester¹, Mariette E.G. Kranendonk¹, Jasper van der Lugt¹, Dannis van Vuurden^{1,*}, Hendrik G. Stunnenberg^{1,*}

*Corresponding authors:

Dannis van Vuurden, D.G.vanVuurden@prinsesmaximacentrum.nl

Hendrik G. Stunnenberg, h.g.stunnenberg@prinsesmaximacentrum.nl

¹Prinses Máxima Centrum for Pediatric Oncology, Utrecht, The Netherlands

²Department of Molecular Biology, Faculty of Science, Radboud University, Nijmegen, The Netherlands

³Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy

⁴University Medical Center Utrecht, Utrecht, The Netherlands

Macrophage (M ϕ) repolarization from a pro-tumor, immunosuppressive phenotype towards an anti-tumor, pro-inflammatory state represents a promising therapeutic strategy in patients with cancer¹. Successful reprogramming of M ϕ in a clinical setting has not been documented. Here, we traced the evolution at single-cell resolution of a diffuse midline glioma (DMG) with H3K27M mutation which metastasized in the abdomen after placing a ventriculoperitoneal (VP) shunt and exploited this information for therapeutic decision-making. The primary tumor showed a complex cellular and genomic landscape characterized by heterogeneous cancer cells and a tumor-supportive immune microenvironment. Upon metastasis, malignant

25 cells populated the peritoneum and triggered a massive anti-inflammatory immune cell
 26 infiltration and expansion of myeloid-derived suppressor cells (MDSCs) in peripheral blood.
 27 Hydroxychloroquine adjuvant treatment started to overcome the immunosuppressive milieu,
 28 which resulted in a decrease in peritoneal cancer cells and pro-tumor innate immune cells.
 29 Importantly, an emergence of anti-tumor, pro-inflammatory macrophages and cytotoxic T-
 30 cells was observed, accompanied by the activation of monocytes in the blood. Our study
 31 advocates the employment of single-cell technologies to better understand and inspire
 32 therapeutic regimens in patients with cancer.

33

34 A child arrived at our center presenting with severe headaches, emesis, and partial abducens nerve
 35 palsy (**Fig. 1a**). A craniospinal MRI scan showed an exophytically growing tumor from the pons
 36 with extension to the right cerebellopontine angle and irregular enhancement with central necrosis,
 37 accompanied by extensive leptomeningeal metastasis in the craniospinal axis (**Fig. 1b**).
 38 Dexamethasone (6 mg/m²/day) was initiated, and at day 7 (d7), a tumor biopsy was taken from two
 39 locations: pons and cerebellar peduncle. The histopathological assessment showed a cell-rich glial
 40 tumor characterized by irregular, hyperchromatic nuclei and diffuse infiltrative growth pattern with
 41 low mitotic activity (**Fig. 1c**). Immunohistochemistry showed tumor cells partially positive for
 42 GFAP, nuclear staining for H3K27M protein with a matching loss of H3K27me3 and a proliferation
 43 index (Ki67) about 30% (**Fig. 1c**). Next-generation sequencing revealed somatic mutations in
 44 *H3F3A* and *TP53*. In addition, DNA methylation profile matched the DMG H3K27M classifier
 45 (score 0,99) and showed high-level amplification of *MET*, *MYC*, and *MDM2* (**Extended Data Fig.**
 46 **1a**) altogether confirming the diagnosis of DMG with H3K27M.

47

48 To gain molecular insights at single-cell resolution, we performed an unbiased exploration of the
 49 primary tumor and its microenvironment (TME) using snRNA-seq, which enables the assessment of
 50 gene expression. Unsupervised analysis of both primary biopsies, taken before initiation of therapy,

identified four main cell groups including tumor cells, immune, vascular and brain resident cells (**Fig. 1d**) as determined by the expression of known marker genes and signatures² per cell type (**Fig. 1e, Extended Data Fig. 1b,c**). We found regional differences in the proportions of tumor cells, with predominantly astrocyte (AC)-like cells in the pons and relatively more oligodendrocyte precursor (OPC)-like cells in the cerebellar peduncle (**Fig. 1d,e**). The genomic makeup of each cancer cell showed marked differences in the copy number variation (CNV), inferred from scRNA-seq pointing to a high degree of clonal diversity that remained hidden in bulk genomic assays (**Fig. 1f and Extended Data Fig. 1a**). These genetically heterogeneous tumor cells are linked to different biological process: hypoxic and invasiveness-related terms in the AC-like cells and MYC-associated and E2F terms for the OPC-like cluster (**Extended Data Fig. 1d**).

The immune component accounted for up to 50% of all cells in both tumor areas and consisted predominantly of tumor-associated myeloid cells (TAMs). These TAMs included few infiltrating blood-derived macrophages (BDM) and a large predominance of resident microglia (MG) (**Fig. 1g**). A fraction (20%) of the MG had a pro-inflammatory profile with higher *TNF* and *IL1B* expression (**Fig. 1h**). Paradoxically, release of pro-inflammatory cytokines by TAMs, such as IL-1 β , stimulates tumor growth and invasion³. An anti-inflammatory phenotype was detected in BDM and MG with a distinctive, tumor-supportive myeloid gene expression pattern with upregulation of *TGFB1*, *CD69*, *IL10RA*, and *CD163* (**Fig. 1h**). The pro- and anti-inflammatory signatures were not mutually exclusive, highlighting the plasticity of the immune myeloid cell compartment. The highly suppressive immune microenvironment generated by myeloid cells likely prevented T cell chemotactic migration given the low number of tumor-infiltrating lymphocytes (TILs) (**Fig. 1d,e**).

Among the scarce T cell infiltrate, we could distinguish CD4 (*CD4*) and CD8 (*CD8A*) cells, with an overall gene expression signature associated with exhausted CD8 characterized by detection of the HMG-box transcription factor TOX, a central regulator of T cell exhaustion⁴, and high co-

77 expression of inhibitory receptors (such as *PDCD1*, *LAG3*, *TIGIT*) (**Fig. 1i**). A small subset of CD8
78 appeared to be an intermediate, transitory state between effector and exhausted T lymphocytes with
79 concomitant expression of the aforementioned exhaustion markers and presence of cytotoxic
80 markers, including *GZMB* and *GZMA* (**Extended Data Fig. 1e**). Such non-conventional TILs state
81 has been previously described in other tumor malignancies⁵ and preventing T cell exhaustion could
82 be used as a therapeutic strategy alongside lifting the immunosuppressive signal from the myeloid
83 compartment.

84
85 During the planning of radiotherapy, the patient's medical condition worsened and a CT scan
86 showed hydrocephalus development (d12). A VP shunt was placed to relieve brain pressure. The
87 patient recovered quickly from the procedure and showed clinical improvement. Based on local
88 guidelines, the patient obtained craniospinal irradiation (IMRT-VMAT), with 54 Gy in 30 fractions
89 on the pontine tumor and 36 Gy on the craniospinal axis with concomitant temozolomide (TMZ -
90 90 mg/m² QD). During radiotherapy, dexamethasone was tapered and stopped. After radiotherapy,
91 TMZ maintenance therapy (200mg/m² QD, five days per month) was established (d52). On d56, the
92 child presented with abdominal pain and swelling. An abdominal ultrasound revealed the presence
93 of ascites. Both for comfort and diagnostics, repetitive drainage of the peritoneal fluid was
94 performed at d67, d78 and d91 (**Fig. 1a**). Cytology of the ascites showed a cell-rich fluid containing
95 macrophages (M ϕ), mesothelial and multiple atypical cells with anisomorphic nuclei, positive for
96 H3K27M and loss of H3K27me3 staining (**Extended Data Fig. 2a**).

97
98 Single-cell profiling confirmed the development of ‘peritoneal glioblastomatosis’ by the presence of
99 metastatic cancer cells together with a massive immune cell component, including M ϕ in various
100 inflammatory states, T lymphocytes and few normal mesothelial cells (**Fig. 2a**). Unsupervised
101 clustering uncovered a complex cellular composition, with various cell states whose relative
102 abundance fluctuated significantly over time (**Fig. 2b and Extended Data Fig. 2b**). Upon closer

inspection of the malignant cell cluster, we identified AC- and OPC-like transcription profiles resembling those seen in the primary pontine tumor. We also observed distinct clones whose affluence varied during the progression of peritoneal metastasis (**Fig. 2c and Extended Data Fig. 2c,d**). We performed trajectory analysis of the metastatic tumor cells unveiling high genomic instability throughout the assessed time window (**Fig. 2d and Extended Data Fig. 2e**). This progression likely reflects cellular adaptations needed to colonize a new, heterotopic habitat and ongoing selective pressure. Cancer cells lost in part their AC-/OPC-like identity, detected by lower levels of signature genes such as *APOE*, *SPARC* and *SI00A10* and underwent metabolic reprogramming during this transition with less dependency on aerobic metabolism, likely driven by *MYC* upregulation (**Extended Data Fig. 2c,d**). These adaptations led to the expansion of clone 4 into the dominant one over time (**Fig. 2c,d**).

In ascites, unsupervised analysis of the M ϕ subcluster revealed what is best described as a continuation of states that display progressive changes in the expression profile and in particular in enriched biological processes (**Fig. 3a and Extended Data Fig. 3a,b**). We detected M ϕ with a characteristic signature of naive cells (*FNCL*, *SI00A8*) and upregulation of chemotactic cytokines such as *IL1B*, *CCL4*, and *CXCL8* in the initial ascites fluid samples (d67 and d78) (**Fig. 3b and Extended Data Fig. 3a**). The pro-tumor phenotype was formed by different cell states with high expression of anti-inflammatory polarization genes (*SELENOP*, *RNASE1*, *SPPI*), chemo-cytokines (*TGFBI*, *CCL2*, *CCL23*) and receptors (*IL10RA*, *CD163*) (**Fig. 3b and Extended Data Fig. 3a**). At d91, M ϕ additionally expressed genes like *FNI* and *MARCO* that are linked with tumor maintenance^{6,7,8} (**Fig. 3b**). The sheer absence of pro-inflammatory-like M ϕ at d91 is accompanied by a sudden reduction in the number of infiltrating peritoneal T cells (**Fig. 2a,b**). These changes unveil the enormous plasticity of cell states that cannot be adequately captured using the canonical M1 and M2 classification scheme. To determine whether this immunological response was mostly constrained to cells in the ascites or held globally, we additionally collected scRNA-seq profiles

from the patient's peripheral blood mononuclear cells (PBMCs). We encountered lymphopenia and monocytoysis with a massive expansion of MDSCs (*S100A8*^{high}, *S100A9*^{high}, and HLA-DR genes^{low}) and relatively fewer non-classical anti-inflammatory monocytes (*CD14*^{low} and *FCGR3A*^{high}) (**Fig. 3c and Extended Data Fig. 3c,d**). We could trace the transition of blood monocytes towards peritoneal infiltrative Mφ, revealing that only classical monocytes (*CD14*^{high}, *FCGR3A*^{low}) are the main source of myeloid infiltrative cells and determine the impact of the peritoneal milieu in the Mφ education to support the local metastatic process by acquiring tumor-nurturing features (**Fig. 3d**).

The generalized tumor-supportive innate immune cells in the brain, ascites and blood led us to search for drugs that could lift the anti-inflammatory nature of the myeloid cells in order to instigate an antitumor phenotype. Hydroxychloroquine (HCQ), a quinolone immunomodulatory drug, has previously been shown to effectively repolarize anti-inflammatory TAMs and boost the tumor-cell killing abilities of Mφ and immune checkpoint inhibitor therapy^{9, 10, 11}. To date, nine clinical trials have been approved to test the efficacy of HCQ as adjuvant therapy¹² including pediatric recurrent low and high-grade gliomas¹³. After informed consent, we started a concomitant therapy at d105 consisting of TMZ and HCQ (50 mg QD for four days, followed by 100 mg QD for eight days).

Remarkably, scRNA-seq profiles of the ascitic fluid taken five days after the initiation of HCQ treatment at d110 showed a sharp reduction in the number of cancer cells, especially those contributing to the proliferative clones 3 and 4. An increase of naïve Mφ and antigen-presenting dendritic cells was accompanied by concomitant reduction of the pro-tumor phenotype (**Fig. 4a and Extended Data Fig. 4a**). Whereas the pro-tumor Mφ, displayed a typical tumor-supportive expression pattern (*MARCO*, *CCL2*, and *SPPI1*), HCQ-activated Mφ expressed the pro-inflammatory genes amphiregulin (*AREG*) and Thrombospondin 1 (*THBS1*) (**Fig. 4b**). This switch was furthermore evident by an overall enrichment of pathways that support myeloid/lymphocyte

155 activation and increased antigen presentation (**Fig. 4c**). Upregulation of *AREG* and *THBS1* has been
 156 associated with activated M ϕ , and their expression enhances cytokine secretion and the induction of
 157 pro-inflammatory pathways^{14, 15, 16, 17}. In addition, other anti-tumor genes, including *FTH1*,
 158 *CXCL16*, *NAMPT* and HLA-DR genes were also highly expressed^{18, 19, 20}.
 159
 160 Before HCQ prescription, pro-tumoral M ϕ were the primary signaling sender in the peritoneal
 161 environment, and the therapeutic intervention changed the pattern and number of cell-cell
 162 interactions with the repolarized M ϕ playing a leading role on the communication networks
 163 (**Extended Data Fig. 4b**). Several of the HCQ-enhanced signaling pathways are correlated with
 164 anticancer immunosurveillance, enhancement in antigen presentation and proinflammatory response
 165 such as MHC-II, ANNEXIN, and THBS pathways^{17, 21, 22} (**Extended Data Fig. 4c**).
 166 Notably, the expansion of CD8 and $\gamma\delta$ T cytotoxic (*NKG7*, *GZMH*) and CD4 cytotoxic/effector
 167 memory cells (*IL7R*, *TNFRSF4*, *GZMK*)^{23, 24} is in line with the HCQ-enhanced chemoattractant
 168 signaling by M ϕ (**Fig. 4d**). Thus, the reduction in the number of cancer cells is likely associated
 169 with the augmented antitumorigenic activity of the immune compartment (myeloid and lymphoid
 170 cells).
 171
 172 In addition, we observed conspicuous changes in PBMCs characterized by near complete reduction
 173 of the number of MDSCs and non-classical monocytes (**Fig. 4e and Extended Data Fig. 4d**). HCQ
 174 treatment restored the homeostasis manifested by the increased number of T and B lymphoid cells
 175 to normal levels as well as by activation of blood monocytes by upregulation of several
 176 inflammatory and tumor suppressor genes, particularly *DUSP1*, *CXCL8*, *NAMPT*, *FOSB*, and
 177 *CCL3L1* (**Fig. 4e,f and Extended Data Fig. 4e**). Gene expression of early growth response-1 and -
 178 2 (EGR1/2; TFs essential for monocyte differentiation, M ϕ commitment, and inflammatory
 179 regulation^{25, 26, 27}) was significantly enhanced in the activated monocytes, further pointing to a
 180 HCQ-induced immune reprogramming (**Fig. 4f and Extended Data Fig. 4e**).

181 Despite these favorable molecular changes in blood and ascites, the patient's condition deteriorated
182 progressively. In part, this was due to an uncontrollable hypalbuminemia, hypokalemia and
183 hypomagnesiemia resulting from the massive loss of protein, electrolytes and fluid. This caused an
184 unmanageable increase in ascites production of up to 3L per day, abdominal pain and multiorgan
185 compromise. The combined treatment was stopped and the patient went home on d118 for palliative
186 care and died five days later. No consent for an autopsy was given.

187
188 In this study, we described the comprehensive single cell profiling and analysis of primary and
189 metastasized DMG tumor cells and their microenvironment. Single cell profiling of periodically
190 collected ascites from the abdominal cavity allowed us to better understand the development of the
191 disease, guide clinical interventions and trace their response at a time-resolved resolution. Our
192 detailed portrait of the primary TME revealed an immunosuppressive innate immune compartment.
193 Additionally, we unveiled the evolution of abdominal metastasis and the local and systemic changes
194 of the immune system before and after the experimental treatment, which allowed for close and
195 repetitive monitoring of the interplay between the immune and metastatic malignant cells, albeit in
196 a heterotopic location. These findings need to be extended to a larger cohort of patients, where
197 similar single-cell profiling is obtained from the TME at diagnosis, during treatment and at autopsy.

198
199 The modulation of the TME, especially the myeloid compartment, has emerged as a promising
200 strategy to overcome the intrinsic and acquire resistance to conventional anticancer therapies in
201 brain tumors. A major challenge needs to be addressed, the brain-blood barrier (BBB) which
202 impedes effective targeting of malignant cells for many drug compounds. Our data points to a pro-
203 inflammatory re-activation of the peritoneal M ϕ and circulating myeloid cells as a strategy to revert
204 the clinicopathological state of the patient. To what extent HCQ treatment changed the TAMs in the
205 pontine region and spinal metastases remains elusive due to the patient's rapid progression. HCQ
206 has been described to cross the BBB to some extent²⁸, but more research is needed to elucidate its

207 immune-modulatory role in DMG patients with and without metastasized disease. Notwithstanding
 208 the positive changes, the aggressiveness of the disease overwhelmed the early response to the
 209 personalized therapy. Overall, our data showcases how single-cell technology provides detailed
 210 molecular insights that can guide therapeutic decision making. Such personalized clinical
 211 interventions are urgently needed to surpass the extremely low survival of patients diagnosed with
 212 aggressive brain tumors.

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233 **References**

234

- 235 1. Bejarano, L., Jordão, M.J.C. & Joyce, J.A. Therapeutic Targeting of the Tumor
236 Microenvironment. *Cancer Discovery* **11**, 933-959 (2021).
- 237 2. Filbin, M.G. *et al.* Developmental and oncogenic programs in H3K27M gliomas dissected
238 by single-cell RNA-seq. *Science* **360**, 331-335 (2018).
- 239 3. Feng, X. *et al.* Loss of CX3CR1 increases accumulation of inflammatory monocytes and
240 promotes gliomagenesis. *Oncotarget* **6**, 15077-15094 (2015).
- 241 4. Khan, O. *et al.* TOX transcriptionally and epigenetically programs CD8(+) T cell
242 exhaustion. *Nature* **571**, 211-218 (2019).
- 243 5. Zheng, C. *et al.* Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell
244 Sequencing. *Cell* **169**, 1342-1356.e1316 (2017).
- 245 6. Dannenmann, S.R. *et al.* Tumor-associated macrophages subvert T-cell function and
246 correlate with reduced survival in clear cell renal cell carcinoma. *Oncoimmunology* **2**,
247 e23562 (2013).
- 248 7. Sa, J.K. *et al.* Transcriptional regulatory networks of tumor-associated macrophages that
249 drive malignancy in mesenchymal glioblastoma. *Genome Biol* **21**, 216 (2020).
- 250 8. La Fleur, L. *et al.* Expression of scavenger receptor MARCO defines a targetable tumor-
251 associated macrophage subset in non-small cell lung cancer. *Int J Cancer* **143**, 1741-1752
252 (2018).
- 253 9. Li, Y. *et al.* Hydroxychloroquine induced lung cancer suppression by enhancing chemo-
254 sensitization and promoting the transition of M2-TAMs to M1-like macrophages. *J Exp Clin*
255 *Cancer Res* **37**, 259 (2018).

256

- 257 10. Hsu, S.P.C. *et al.* Rapamycin and hydroxychloroquine combination alters macrophage
258 polarization and sensitizes glioblastoma to immune checkpoint inhibitors. *J Neurooncol*
259 **146**, 417-426 (2020).
- 260 11. Chen, D. *et al.* Chloroquine modulates antitumor immune response by resetting tumor-
261 associated macrophages toward M1 phenotype. *Nat Commun* **9**, 873 (2018).
- 262 12. National Cancer Institute. Clinical Trials Using Hydroxychloroquine. 2021 [cited January
263 22, 2021]Available from: [https://www.cancer.gov/about-cancer/treatment/clinical-](https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/hydroxychloroquine)
264 [trials/intervention/hydroxychloroquine](https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/hydroxychloroquine)
- 265 13. ClinicalTrials.gov. A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients
266 With Recurrent LGG or HGG With a BRAF Aberration. 2021 [cited January 22,
267 2021]Available from: <https://clinicaltrials.gov/ct2/show/NCT04201457>
- 268 14. Meng, C. *et al.* Amphiregulin may be a new biomarker of classically activated macrophages.
269 *Biochem Biophys Res Commun* **466**, 393-399 (2015).
- 270 15. Xu, Y. *et al.* Classically Activated Macrophages Protect against Lipopolysaccharide-induced
271 Acute Lung Injury by Expressing Amphiregulin in Mice. *Anesthesiology* **124**, 1086-1099
272 (2016).
- 273 16. Melderis, S. *et al.* Amphiregulin Aggravates Glomerulonephritis via Recruitment and
274 Activation of Myeloid Cells. *J Am Soc Nephrol* **31**, 1996-2012 (2020).
- 275 17. Xiao, M., Zhang, J., Chen, W. & Chen, W. M1-like tumor-associated macrophages activated
276 by exosome-transferred THBS1 promote malignant migration in oral squamous cell
277 carcinoma. *J Exp Clin Cancer Res* **37**, 143 (2018).
- 278 18. Corna, G. *et al.* Polarization dictates iron handling by inflammatory and alternatively
279 activated macrophages. *Haematologica* **95**, 1814-1822 (2010).
- 280 19. Kee, J.Y. *et al.* CXCL16 suppresses liver metastasis of colorectal cancer by promoting TNF-
281 alpha-induced apoptosis by tumor-associated macrophages. *BMC Cancer* **14**, 949 (2014).
- 282

- 283 20. Cameron, A.M. *et al.* Inflammatory macrophage dependence on NAD(+) salvage is a
284 consequence of reactive oxygen species-mediated DNA damage. *Nat Immunol* **20**, 420-432
285 (2019).
- 286 21. Stein, E.V., Miller, T.W., Ivins-O'Keefe, K., Kaur, S. & Roberts, D.D. Secreted
287 Thrombospondin-1 Regulates Macrophage Interleukin-1beta Production and Activation
288 through CD47. *Sci Rep* **6**, 19684 (2016).
- 289 22. Baracco, E.E. *et al.* Contribution of annexin A1 to anticancer immunosurveillance.
290 *Oncoimmunology* **8**, e1647760 (2019).
- 291 23. Szabo, P.A. *et al.* Single-cell transcriptomics of human T cells reveals tissue and activation
292 signatures in health and disease. *Nat Commun* **10**, 4706 (2019).
- 293 24. Oh, D.Y. *et al.* Intratumoral CD4(+) T Cells Mediate Anti-tumor Cytotoxicity in Human
294 Bladder Cancer. *Cell* **181**, 1612-1625 e1613 (2020).
- 295 25. Trizzino, M. *et al.* EGR1 is a gatekeeper of inflammatory enhancers in human macrophages.
296 *Science Advances* **7**, eaaz8836 (2021).
- 297 26. Veremeyko, T., Yung, A.W.Y., Anthony, D.C., Strekalova, T. & Ponomarev, E.D. Early
298 Growth Response Gene-2 Is Essential for M1 and M2 Macrophage Activation and Plasticity
299 by Modulation of the Transcription Factor CEBPβ. *Frontiers in Immunology* **9** (2018).
- 300 27. Mendes, K. *et al.* The epigenetic pioneer EGR2 initiates DNA demethylation in
301 differentiating monocytes at both stable and transient binding sites. *Nature Communications*
302 **12**, 1556 (2021).
- 303 28. Mascolo, A. *et al.* Neuropsychiatric clinical manifestations in elderly patients treated with
304 hydroxychloroquine: a review article. *Inflammopharmacology* **26**, 1141-1149 (2018).

305
306

307

308

309

310 **Methods**

311

312 **Index patient.** The patient's parents gave and signed the informed consent to the protocols
 313 performed in this study and publication of the results from analyses generated on the collected
 314 biological samples. Hydroxychloroquine (HCQ) is registered for the pediatric population to treat
 315 juvenile idiopathic arthritis, discoid and systemic lupus erythematosus, with a maximum dose of 6.5
 316 mg/kg/day. The patient received a dose below this maximum allowed. Considering the lack of
 317 alternative treatments for this lethal disease and the well-known safety profile of this drug in
 318 children, off-label use of HCQ was considered feasible, and no additional approval was needed for
 319 its implementation in the patient. The research protocols and reported results followed the CARE
 320 guidelines (<https://www.care-statement.org>), and medical care complied with the Declaration of
 321 Helsinki principles.

322

323 **Sampling human materials.** Neuronavigational biopsy of the primary tumor was taken via
 324 retrosigmoidal route from the right side of the head. Initially, sampling of the deeper part of the
 325 tumor (pontine region) was taken, followed by an additional biopsy towards the tumor's periphery
 326 (cerebellar peduncle area). In the beginning, ascitic fluid was obtained by repeated drainage via
 327 paracentesis using a sterile technique. When the accumulation of free abdominal fluid increased, a
 328 palliative long-term abdominal drain was placed surgically, and samples were conserved sterile on
 329 the collection system. Peripheral blood mononuclear cells (PBMCs) were obtained from fresh blood
 330 samples.

331

332 **Cell isolation and handling.** Primary tumor biopsies were immediately placed in warm “tumor
 333 medium” (Advanced DMEM/F12, Penicillin Streptomycin, GlutaMAX, HEPES Buffer Solution;
 334 Gibco Laboratories) and divided for histopathological analysis and molecular diagnosis
 335 (immunohistochemistry, methylome profiling and whole-exome sequencing). A small fraction was

336 stored in freezing medium containing 90% fetal bovine serum (FBS; Gibco Laboratories) plus 10%
 337 DMSO (Sigma-Aldrich) for later single-nuclei isolation. For the ascites, the total volume collected
 338 from the abdominal puncture or drainage system was immediately centrifuged at 300g for 10 min at
 339 room temperature (RT) and washed three times (300g, 10min at RT) with tumor medium. In case
 340 that the recovered cells had a high amount of red blood cells (RBCs >30% of the total), an RBC
 341 lysis solution was used (Miltenyi Biotec). PBMCs were isolated using a density-gradient medium
 342 (Lymphoprep, Stem Cell Technologies) from fresh EDTA peripheral blood. Cells obtained from the
 343 ascitic fluid and PBMCs were either processed immediately for sn/scRNA or immediately placed in
 344 freezing medium (peritoneal cells: tumor medium plus 10% DMSO; PBMCs: 40% RPMI Medium,
 345 50% FBS plus 10% DMSO) and stored at -80 °C or liquid nitrogen for later use. Summary of the
 346 samples was placed in Supplementary Table 5.

347

348 **Immunohistochemistry.** The patient's tumor was formalin-fixed and embedded in paraffin (FFPE),
 349 sectioned at 4 µm, and stained with hematoxylin and eosin. Immunohistochemical staining using
 350 antibodies against Glial fibrillary acidic protein (GFAP) (DAKO, M0761, clone 6F2, L42907,
 351 Ventana 1:1000), neurofilament (Monosan 3004-1, clone 2F11, L0420H, 1:800), H3.3K27M
 352 (Abcam, ab19063, clone BPR18340, LGR3333170-1, 1:1000), H3 K27me3 (cell signaling, 9733S,
 353 clone C36B11, L16, 1:25), Ki67 (Ventana, 790-4286, clone Ki67, LE07920, Ventana, ready to use)
 354 were performed on the FFPE slides in the BenchMark ULTRA (Ventana), according to diagnostic
 355 procedure protocols used at the pathology department of the University Medical Center in Utrecht,
 356 the Netherlands. Stainings were evaluated by two independent pathologists.

357

358 **Cytology.** Three to five cytopsins of the freshly collected ascitic fluid were made and stained using
 359 Giemsa and Papanicolaou methods for cytologic evaluation and H3K27M and H3K27me3 to
 360 determine peritoneal metastasis from the primary malignancy, as written above.

361

362 **Whole-genome methylation array.** After DNA isolation and bisulfite conversion
 363 MethylationEPIC (850K) BeadChip platform (Illumina) as described by Capper et al. (2018), was
 364 used to detect methylation²⁹. Copy number variations were determined using the Conumee package
 365 in R as previously described²⁹. The profile was matched with the Classifier using the current version
 366 at the time of original upload (v11b4 - www.molecularneuropathology.org)
 367
 368 **Whole exome sequencing.** Whole-exome sequencing libraries were generated using the KaPa
 369 hyperprep kit in combination with the HyperExome capture kit (Roche). Libraries were sequenced
 370 on a NovaSeq (Illumina) using 2x150 bp paired-end sequencing. Reads were mapped against the
 371 hg38 human genome using BWA with default parameters. Obtained CRAM files were converted
 372 into BAM files using samtools³⁰ (v1.11), and genome-wide copy number calling performed using
 373 CNVkit³¹ (v 0.9.8) with default parameters.
 374
 375 **Nuclei isolation and live-cell enrichment for single-cell omics.** For the nuclei isolation from the
 376 primary tumor to perform snRNA-seq, samples were thawed in a water bath at 37 °C for two
 377 minutes, washed with tumor medium, and spun down at 350g for 5 min. The cell pellet was placed
 378 on 500µl of Nonidet P40 with salts and Tris (NST) lysis buffer³² (Tris-HCl pH 7.4 1M, NaCl
 379 146nM, MgCl₂ 21nM, CaCl₂ 1mM, NP40 0.1%, 0.2 U/µl RNasin Plus Inhibitor, Promega) and
 380 homogenized on ice using a glass-on-glass Dounce homogenizer with five strokes using the loose
 381 pestle, followed by ten strokes of the tight pestle. An additional 1 ml of the NST lysis buffer
 382 solution was added, gently mixed, and incubated for 5 min on ice. Nuclear homogenates were
 383 filtered through a 70µm Flowmi cell strainer (Bel-Art) and centrifuged for 5 min at 500g, at 4 °C.
 384 The pellet was resuspended in wash buffer (NST lysis buffer with no NP40 plus 1% bovine serum
 385 albumin; Sigma-Aldrich), and the added volume was dependent on the size of the pellet usually
 386 within 200–300 µl. Nuclei solution was filtered with a 40µm Flowmi cell strainer (Bel-Art) and

387 counted using Trypan blue staining 0.1% on a Countess II Automated Cell Counter (Thermo Fisher
388 Scientific) before sorting.

389 In the case of scRNA-seq, fresh samples were washed with a warm medium (Advanced
390 DMEM/F12 for ascites or RPMI for PBMCs, both supplemented with 10% FBS) and pelleted three
391 times. Cryopreserved cells were initially thawed in a water bath at 37 °C for two minutes, washed
392 with warm medium, and spun down at 350g for 5 min, followed by three other washing steps. The
393 cell pellet was resuspended, for both fresh and cryopreserved samples, in an appropriate volume of
394 sterile PBS (Sigma-Aldrich) supplemented with 0.04% BSA (Sigma-Aldrich) to obtain a
395 concentration of 1,200-1,500 cells/μl. Cell viability was determined using Trypan blue staining
396 0.1% and assessed on a Countess II Automated Cell Counter (Thermo Fisher Scientific). In case of
397 low viability (<70%) of the ascitic cells or PBMCs (fresh or cryopreserved), the Dead Cell Removal
398 Kit (Miltenyi Biotec) was used according to the manufacturer's protocol (Supplementary Table 5).

399
400 **Fluorescence-activated nuclei sorting (FANS).** Nuclei were stained with DAPI 1:200 dilution
401 (2μg/ml stock concentration; Sigma-Aldrich) 5min at RT before sorting. FANS was done on a Sony
402 SH800 cell sorter (Sony Biotechnology) using a 100μm nozzle. All events were gated with the
403 consecutive gates: (1) forward scatter-area (FSC-A)/back scatter-area (BSC-A) (2) DAPI-H-
404 compensated/DAPI-A-compensated and (3) BSC-A/DAPI-A-compensated. The last gate was used
405 to select singlets. Nuclei were sorted directly into the RT Buffer for Single Cell Gene Expression 3'
406 v3 reagents (10x Genomics) without the RT enzyme (added later prior to droplet encapsulation).
407 The FANS settings were as follows: mode – normal, sorting pressure – 5, number of sorted nuclei –
408 12,000.

409
410 **Droplet-based sc/snRNA-seq.** For sc/snRNA-seq, Single Cell Gene Expression 3' v3 (10x
411 Genomics) was used for single-cell/nuclei capturing and library construction, as described in the
412 Genomics Single Cell RNA Reagent Kits User Guide. Briefly, either 12,000 single nuclei (primary

tumor) or 12,000 to 17,000 single cells (ascites/PBMCs) were loaded into a channel of a Chromium Single Cell Gene Expression 3' Chip. Single cells/nuclei were partitioned into droplets with gel beads in the Chromium Controller to generate single-cell/nuclei gel bead-in-emulsion (GEM) followed by barcoded reverse transcription of RNA. This was followed by cDNA amplification, fragmentation and adapter, and sample index ligation. Quality of the sc/snRNA-seq libraries were assessed on a 2100 Bioanalyzer (Agilent) and sequenced on a NextSeq500 or NovaSeq (Illumina).

sn/scRNA-seq data processing and analysis. To demultiplex the raw BCL files, we used Cell Ranger mkfastq (v3.1.0) to generate the FASTQ files. Each sample was mapped to the human reference genome (GRCh38 v3.0.0) provided by 10x Genomics using the Cell Ranger count with default parameters to obtain the gene count matrix. For single nuclei samples, the reference for pre-mRNA was created using the manufacturer's guidelines (<https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/advanced/references>) A summary of the quality metrics per sample was placed in Supplementary Table 6. To generate the unspliced/spliced mRNA matrix from the BAM files needed for expression dynamics via RNA velocity inference, we used the velocity³³ (v0.1.7) command-line tool.

We analyzed the expression matrices using Seurat package³⁴ (v4.0) with default parameters unless specified otherwise. For downstream analysis, only genes expressed in at least five cells were included, and nuclei/cells with a number of genes > 200(nuclei)/500 (cells) and percentage of mitochondrial reads (MT) < 20% were kept (Supplementary Table 7 and Supplementary Fig. 1). DoubletFinder³⁵ (v2.0.3) was used in each sample to exclude doublets, and the multiplet rate formation was selected based on 10x Genomics estimations and adjusted individually according to the number of recovered cells per library. On PBMCs, we found a scattered detection of platelet genes (*PPBP*, *TUBB1*, *PF4*, *GNG11*) over other cell clusters and did not form a well-clustered platelet population; we filtered out cells that have jointed expression of the genes mentioned above and gene markers defining other cell identities and were considered doublets.

Once the singlets were obtained, the datasets were normalized using SCTransform³⁶ (v0.3.2.9), regressing out the MT percentage content. For data integration, fastMNN³⁷ (part of SeuratWrappers v0.3.0) was applied with default settings. We used Uniform Manifold Approximation and Projection (UMAP) for dimension reduction and shared nearest neighbor (SNN) graph-based clustering resolution optimized for each combined dataset. We applied a Wilcoxon rank-sum test within the Seurat framework to find the differential expressed genes (DEGs) between clusters. On ascites, after integrating all datasets, we found a group of cells that had low complexity (lower number of genes and UMI) and were mainly coming from the samples where the cell viability was lower than 70% (after dead cell removal - Supplementary Table 5). We suspected those clusters were mainly formed by nuclei and confirmed their identity looking at the spliced/unspliced ratio displaying a higher number on unspliced transcripts (~50%), typically seen in nuclei but not in cells (~20%). These cells (nuclei) were filtered out of the downstream analysis.

To annotate the different cell types, three approaches were used: (1) known genes of non-malignant cells and previously published malignant cells signatures², (2) SingleR³⁸ (v1.4.0), an automated annotation package, and (3) multimodal reference mapping implemented in Seurat to annotate cells based on reference-defined cell types. To confirm the malignant cells' identity, we inferred the copy number of variation (CNV) from single-cell gene expression data using inferCNV³⁹ (v1.7.1). On a sample-by-sample basis, we used the cells that were part of the TME (immune, vascular, resident tissue cells) as a healthy reference to estimate CNVs in the malignant cells. Gene expression of normalized values was represented using either heatmap, violin, bar, or density plots, the last ones produced by the Nebulosa⁴⁰ package. Gene set enrichment analysis (GSEA) of hallmark gene sets was performed using escape⁴¹ (v1.1.1) that performs enrichment in individual cells via ssGSEA. Gene ontology (GO) analysis was carried out with EnrichR within the Cerebro⁴² (v1.3.0) package using the precomputed Seurat object. Cell-cell communication networks were inferred by CellChat⁴³ (v0.5.5) with default parameters and ligand-receptor interaction databases. Bar, area, contour, and donut plots were generated using ggplot2 (v2.3.3) and webr (v0.1.6) packages. To make use of tools

465 developed within the Python language, the data was exported as loom file and read into the
466 Scanpy⁴⁴ (v1.6) toolkit for visualization purposes, scVelo⁴⁵ (v0.2.2) for RNA velocity analysis, and
467 STREAM⁴⁶ (v1.0) for trajectory inference analysis. All analyses were performed using R (v4.0.3)
468 and Python (v3.7.8).

469

470 **Data availability**

471 Raw data and filtered matrix files for the sn/scRNA-seq have been deposited as a series in the NCBI
472 Gene Expression Omnibus under accession number GSE168548. All other data are available from
473 the corresponding author upon reasonable request.

474

475 **Code availability**

476 Code used to perform analysis and generate the figures will be publicly available from GitHub
477 (https://github.com/ccruizm/DMG_2021).

478

479 **References**

480

481 29. Capper, D. *et al.* DNA methylation-based classification of central nervous system tumours.
482 *Nature* **555**, 469-474 (2018).

483 30. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078-
484 2079 (2009).

485 31. Talevich, E., Shain, A.H., Botton, T. & Bastian, B.C. CNVkit: Genome-Wide Copy Number
486 Detection and Visualization from Targeted DNA Sequencing. *PLoS Comput Biol* **12**,
487 e1004873 (2016).

488 32. Slyper, M. *et al.* A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen
489 human tumors. *Nat Med* **26**, 792-802 (2020).

490 33. La Manno, G. *et al.* RNA velocity of single cells. *Nature* **560**, 494-498 (2018).

491

- 492 34. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *bioRxiv*,
493 2020.2010.2012.335331 (2020).
- 494 35. McGinnis, C.S., Murrow, L.M. & Gartner, Z.J. DoubletFinder: Doublet Detection in Single-
495 Cell RNA Sequencing Data Using Artificial Nearest Neighbors. *Cell Syst* **8**, 329-337 e324
496 (2019).
- 497 36. Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-
498 seq data using regularized negative binomial regression. *Genome Biology* **20**, 296 (2019).
- 499 37. Haghverdi, L., Lun, A.T.L., Morgan, M.D. & Marioni, J.C. Batch effects in single-cell
500 RNA-sequencing data are corrected by matching mutual nearest neighbors. *Nat Biotechnol*
501 **36**, 421-427 (2018).
- 502 38. Aran, D. *et al.* Reference-based analysis of lung single-cell sequencing reveals a transitional
503 profibrotic macrophage. *Nat Immunol* **20**, 163-172 (2019).
- 504 39. Tickle, T.I., Georgescu, C., Brown, M. & Haas, B. inferCNV of the Trinity CTAT Project.
505 2019.
- 506 40. Alquicira-Hernandez, J. & Powell, J.E. Nebulosa recovers single-cell gene expression
507 signals by kernel density estimation. *Bioinformatics* (2021).
- 508 41. Borchertding, N. *et al.* Mapping the immune environment in clear cell renal carcinoma by
509 single-cell genomics. *Communications Biology* **4**, 122 (2021).
- 510 42. Hillje, R., Pelicci, P.G. & Luzi, L. Cerebro: interactive visualization of scRNA-seq data.
511 *Bioinformatics* **36**, 2311-2313 (2020).
- 512 43. Jin, S. *et al.* Inference and analysis of cell-cell communication using CellChat. *Nature*
513 *Communications* **12**, 1088 (2021).
- 514 44. Wolf, F.A., Angerer, P. & Theis, F.J. SCANPY: large-scale single-cell gene expression data
515 analysis. *Genome Biol* **19**, 15 (2018).
- 516

45. Bergen, V., Lange, M., Peidli, S., Wolf, F.A. & Theis, F.J. Generalizing RNA velocity to transient cell states through dynamical modeling. *Nature Biotechnology* **38**, 1408-1414 (2020).
46. Chen, H. *et al.* Single-cell trajectories reconstruction, exploration and mapping of omics data with STREAM. *Nat Commun* **10**, 1903 (2019).

Acknowledgments

The authors are profoundly grateful to the patient and his family who contributed to this work, which has set the basis for future research. This manuscript is dedicated to his memory. We thank Marc van Wetering and Femke C.A. Ringnalda for the help and assistance in tissue acquisition. C.R.M. is supported by the Princess Maxima Center and the European Union's Horizon 2020 Skłodowska-Curie Actions (project AiPBAND) under grant #76428. F.K. is supported by ZonMW-TOP project 91-21-6061. W.M. is supported by the Italian National Operational Programme on Research 2014-2020 (PON AIM 1859703-2). D.v.V and H.G.S. are supported by the Princess Maxima Center and Kika (Kinderen Kankervrij).

Author contributions

C.R.M. contributed to the study design, performed experiments and bioinformatic analysis. F.K., P.B., and B.t.P. contributed with experimental work and W.M with bioinformatic analysis. J.vd L., K.B., H.C.B. and D.v.V. provided clinical data, sample collection and patient care. M.E.G.K and L.K. performed pathological analysis. D.v.V. and H.G.S. conceived and designed the study and experiments. C.R.M. and H.G.S. wrote the manuscript. All authors read and approved the manuscript.

543 **Competing interests**

544

545 The authors declare no competing interests.

546

547

548

549 Figures and legends

550

Fig 1. Single-cell transcriptomics analysis reveals tumor heterogeneity and supportive TME in primary DMG with H3K27M mutation. **a**, Scheme of the clinical course. WES, whole-exome sequencing. Created with BioRender.com **b**, Sagittal and transverse MRI T1-enhanced plane. White arrows point to the leptomeningeal metastasis, red arrows to the focal necrosis and green stars mark the regions where biopsies were taken. MRI, magnetic resonance imaging. **c**, Immunohistochemistry staining of DMG H3K27M protein markers at time of diagnosis. H&E, hematoxylin, and eosin. Scale bar, 100µm. **d**, UMAP projection of the expression profiles of 5,422 nuclei collected from the pons (left) and cerebellar peduncle (CP; right) tumor regions. Cells were clustered and colored by cluster identity. UMAP, uniform manifold approximation and projection. **e**, Expression levels (y-axis) of cell type marker genes. Violin plots show the normalized expression levels per marker gene and are colored by cell type. The histograms display the number of cells per cluster (middle) and the relative abundance of each cluster per tumor region (right). **f**, Clustered heatmap of inferred CNV profiles of the AC- ($n=694$) and OPC-like ($n=357$) cancer cells, colored by copy number gain (red) and loss (blue) at each chromosomal bin of 100 genes (columns) across snRNA-seq profiled cells (rows). Separated into genetic subclones based on CNV pattern. Bottom panel: copy number profile derived from bulk exome sequencing data. CNV, copy number variation. **g**, Subclustering of the TAM cluster into microglia (1; green) and blood-derived macrophages (2; orange). On the bottom, density plots of the cell clusters of the two tumor areas. Violin plots display four marker genes for the two subclusters. **h**, Selected feature plots of pro- and anti-inflammatory genes in the TAMs cluster, colored by normalized gene expression. **i**, Gene expression plots of T cell exhaustion markers in the TILs cluster, colored by normalized gene expression.

Extended Data Fig. 1. Gene expression profiling of primary DMG tissue. a, CNV profile of all autosomes inferred from DNA methylation data. CNV, copy number variation. Y-axis shows estimated copy number gain or loss. Amplified oncogenes are highlighted with a green star. **b**, Heatmap of the five top ranking marker genes per cluster (related to Fig. 1e, see also Supplementary Table 1). **c**, UMAP plot of the primary tumor, colored by the enrichment for specific DMG H3K27M signatures defined by Filbin et al. (2018)². UMAP, uniform manifold approximation and projection. **d**, PCA of GSEA of the "hallmark gene set" collection from the MSigDB per cell within each malignant state, colored by cell counts. Top hallmarks that explain the shift of the cells are embedded in the PC dimension reduction plot. PCA, principal component analysis; GSEA, gene set enrichment analysis. **e**, Normalized gene expression of effector genes in TILs.

594

595 **Fig 2. Cell diversity of the ascitic fluid and transcriptomic cancer cell adaptation upon**

596 **abdominal metastasis. a**, Integrated UMAP embedding of scRNA-seq profile of 21,704 cells

597 collected from the peritoneal fluid collected at day67, day78 and day91. Cells are color-coded by

598 cluster identity. UMAP, uniform manifold approximation and projection. **b**, Violin plots depict the

599 normalized expression (y-axis) of known marker genes (x-axis) per cluster. Histograms display the
600 cell count per cluster (middle panel) and their relative abundance per time point (right panel),
601 respectively. **c**, UMAP of all cells that were inferred to be malignant ($n = 7,860$). Five subclusters
602 putatively resembling the primary tumor, early and late clones are shown. Bottom panel: Cell
603 density plots at three time points of ascites profiling. Right panel: UMAP of the malignant cell
604 component, with cells colored by their enrichment for specific DMG H3K27M signatures defined in
605 Filbin et al. (2018). UMAP, uniform manifold approximation and projection. **d**, Stream plot
606 depicting tumor evolution in pseudo-time (x-axis). The y-axis depicts the number of cells at that
607 timepoint. Colors represent the clonal identity. The timepoints at which clones gain (red color) or
608 lose (blue color) copy numbers are annotated for specific loci. Clonal identity and copy number
609 variation were inferred from snRNA-seq data (methods).

610

611

612

613

614

615

616

617

618

619

620

621

622

Extended Data Fig. 2. Transcriptional signatures point to diverging tumor clones and cell adaptations. **a**, Cytology of the ascitic fluid and staining of protein markers detected in the primary tumor. MGG, May Grunwald-Giemsa. Scale bar, 80µm. **b**, Single-cell-resolution heatmap of the top five highly enriched genes per cell cluster in ascites, identifying the cell subsets labeled in Fig. 2a,b (Supplementary Table 2). **c**, Gene expression heatmap within the cancer subclusters.

628 Significantly up- and downregulated genes are plotted as the average expression per cell cluster.
629 The dot's size represents the percentage expression, and the dendrogram highlights the four main
630 evolutionary categories. **d**, Heatmap displays GSEA of individual metastatic peritoneal cells using
631 the “hallmark gene set” collection from the MSigDB. Cell are colored by enrichment score and
632 hierarchically clustered within each cell identity and timepoint. GSEA, gene set enrichment
633 analysis. **e**, Detailed inferred CNV profiles that identified the clones depicted in Fig. 2d (also shown
634 in the inset). Chromosomal amplification (red) and deletion (blue) inferred in each chromosome
635 (columns) across single cells (rows). Top: reference cells not expected to contain CNV in the
636 peritoneal fluid (immune and mesothelial cells). Bottom: cells tested for CNV relative to the
637 reference. Dendrogram highlights each main cell clone. CNV, copy number variation.

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

657 **Figure 3. Immune cell dynamics in ascites and peripheral blood. a**, RNA velocity UMAP of
658 macrophages ($M\phi$, $n = 9,324$) collected from ascites. Cells are colored by cell cluster (left), density
659 time point (right). Tracks and arrows represent the developmental trajectory inferred by RNA velocity
660 analysis (Methods). UMAP, uniform manifold approximation and projection. **b**, Selected marker
661 genes that discriminate $M\phi$ states, colored by normalized gene expression (see Extended Data Fig.
662 3a). **c**, scRNA-seq analysis on 7,232 PMBCs colored by inferred cell type. Right panel: gene
663 expression of canonical marker genes for MDSCs and non-classical monocytes. MDSCs, myeloid-
664 derived suppressor cells; PMBCs, peripheral blood mononuclear cells. **d**, RNA velocities derived
665 from the dynamical model for blood-monocyte-to-peritoneal- $M\phi$ are projected into a UMAP-based
666 embedding and color-coded by cell identity. On the right, heatmap of dynamic anti-inflammatory
667 driver genes of the transition of cells from blood monocytes towards tumor-supportive peritoneal $M\phi$.
668

Fig 4. HCQ decreases the number of abdominal cancer cells and lifts the immunosuppressive status regionally and systemically. **a**, UMAP of single-cell transcriptomes obtained from ascites that was collected before- (d91, $n = 7,570$) and after HCQ treatment (d110, $n = 7,050$; and d117, $n = 5,184$). Dotted lines surround the main cell types that display significant changes after treatment. UMAP, uniform manifold approximation and projection. **b**, Volcano plot of genes that are differentially expressed between pro-tumoral- and activated M ϕ . P value was derived by Wilcoxon's rank-sum test. DEGs per cluster are listed in Supplementary Table 3. **c**, Highest enriched GO terms for genes upregulated in pro-tumoral- (purple) and activated M ϕ (red). **d**, Subsetting and reclustering of the lymphoid cluster. Bottom panel: cell densities at day 91 (before HCQ), day 110 and day 117 (after HCQ). Right panel: gene expression bar plot of each individual cell. Normalized gene expression is represented by height. **e**, scRNA-seq analysis and clustering of PBMCs of the timepoint before HCQ treatment (d91, $n = 7,232$) and after experimental therapy (d110, $n = 3,856$; and d117, $n = 9,024$), and colored by cell identity. Dotted lines surround the main cell types that display significant changes after treatment. A list of DEGs per cluster is provided in Supplementary Table 4. **f**, Volcano plot showing the average gene expression and fold change ($\log_2$) between activated monocytes and CD14 monocytes/MDSCs. P value: Wilcoxon's rank-sum test. MDSCs, myeloid-derived suppressor cells.

Extended Data Fig. 4. HCQ affects cell proportions and cell-cell interaction networks in ascites and peripheral blood. **a**, Area chart showing the relative abundance of each cell cluster identified in the snRNA-seq profiles from ascitic fluid collected on day91, day110 and day117. **b**, Heatmap plot of the differential number of interactions (left) and interaction strength (right) among the different cell types in the peritoneal milieu. **c**, Cell-cell communication in the peritoneal milieu. Significant signaling pathways were ranked based on their overall information flow differences within the inferred networks between pre- and post-HCQ. The top signaling pathways pre-HCQ are colored in blue, whereas those enriched in post-HCQ are colored in orange. On the right, the circle plots zoom-in on the main signaling pathways with pathophysiological relevance after HCQ, among immune and malignant cells. **d**, Area chart showing the relative abundance of each cluster identified in PBMCs at day91, day110 and day117. **e**, Feature plots of selected genes that were upregulated in the activated monocytes in blood. Cells are colored by normalized gene expression.

732 **Supplementary Information**

733

734 1. List of Supplementary Tables

735

736 ▪ **Supplementary Table 1.** List of the differentially expressed genes (DEGs) in primary
737 tumor cell clusters (separate Excel file).

738 ▪ **Supplementary Table 2.** List of the DEGs in cell types detected in ascites before treatment
739 with hydroxychloroquine (HCQ) (separate Excel file).

740 ▪ **Supplementary Table 3.** List of the DEGs between pro-tumor and HCQ-activated Mφ
741 (separate Excel file).

742 ▪ **Supplementary Table 4.** List of the DEGs in cell types/states in PBMCs before and after
743 treatment with hydroxychloroquine (HCQ) (separate Excel file).

744 ▪ **Supplementary Table 5.** Summary of information on samples profiled by single-cell RNA
745 seq (separate Excel file).

746 ▪ **Supplementary Table 6.** Summary of information on sequencing output and overall quality
747 metrics from CellRanger (separate Excel file).

748 ▪ **Supplementary Table 7.** Filtration criteria of sn/scRNA-seq datasets to exclude cells with
749 low quality and doublets (separate Excel file).

750

751

752

753

754

2. Supplementary Figure Legends

- Supplementary Figure 1. Scatter plots displaying cutoffs for filtering out low-quality cells from sn/scRNA-seq datasets.** Scatter plots show the number of unique molecular index (UMI) vs. number of genes in each cell. Cells are colored by the percent of mitochondrial (MT) genes. Red dashed lines depict the upper and lower limits on each axis. Red arrowheads point to the max percent of MT allowed in each nucleus/cell. Highlighted red area represents the cells used on the downstream analysis (next step, doublet cell removal). Number of cells in each sample is in Supplementary Table 7 ('nCell after QC filtering' column).